EN DE
Watch IXICO PLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

IXICO PLC (IXI) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of IXICO PLC stock £0.11, price £0.13, that is 15.5% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00BFXR4C20

IP IXICO PLC logo Thin data Nov 10, 2026

IXICO PLC

IXI · LSE

Expensive (fair value 16% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Ranks above peers (6/9) 
Revenue last quarter +23% vs. a year ago. 
Quality 40/100 
Fair value £0.1078 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −7.3 %/yr in GBP) 
Loss-making · -25.0% net margin (TTM) 
Negative free cash flow 
Narrow moat 12/100 · thin data
Thin data 
Estimate
Watch IXICO PLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£0.8450 £0.0645 Fair Value £0.1078 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range £0.0645 – £0.8450 · fair‑value band £0.0809 – £0.1348 · the £0.1275 price screens above the £0.1078 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow IXICO in your weekly email

Every Wednesday you see whether IXICO is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally.

Show moreShow less

The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services.

It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services.

In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis.

Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders.

It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.

Stock analysis

IXICO PLC (IXI) currently trades at £0.1275, while our estimate is £0.1078, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: £0.0809 (bear) to £0.1348 (bull), the price of £0.1275 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

IXICO PLC reported revenue of £6.5M in FY2025 versus £9.2M in FY2021, a compound −8.2%/yr. Reported net income was −£1.7M in FY2025.

Key figures

Market cap £27.9M Micro · P/S ratio 3.54 · EPS (TTM) £−0.0200 · Net margin −25.0% · Return on equity −15.8% · Return on assets (EBIT) −6.9% (5-year average) · Operating margin −31.4% · Revenue (TTM) £7.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 92% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −16%, IXI screens richer than that median.

Fair Value

Bear £0.0809 Fair Value £0.1078 Bull £0.1348
Price £0.1275 · Downside -15.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 66
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 62
Distance to the 52-week high, does not count
New shares 22
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+13.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.3%
Start year 2020 (pandemic). Over 10 years: +7.7% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.5% (2020) → −38.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IXI screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare IXICO PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside −15.5% · Above median
Profitability
Return on assets −11.9% · Above median
Net margin (12 months) −25.0% · Below median
Operating margin (12 months) −31.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 23.1% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.38× · Cheaper than median
P/S (12 months) 3.84× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs IXI
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs IXI
Samsung Biologics Co 207940 1,411,000 KRW 1,573,000 KRW +11% vs IXI
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs IXI
argenx SE ARGX $960.04 $908.40 −5% vs IXI
CSL Limited CSL A$202.92 A$183.54 −10% vs IXI
Moderna, Inc MRNA $223.37 $139.99 −37% vs IXI
BeOne Medicines AG 6160 HK$249.80 HK$152.80 −39% vs IXI
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs IXI
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs IXI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

IXICO PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "IXICO PLC Fair Value". https://www.fairvalue-calculator.com/stock/IXI

Frequently asked questions

Is IXICO PLC (IXI) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is £0.1078 versus a price of £0.1275, about 16% lower (overvalued).
What is the fair value of IXI?
Our estimate for IXICO PLC is £0.1078 (as of Nov 10, 2026), built from audited fundamentals. The current price: £0.1275.
What is the quality score of IXI?
IXICO PLC has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IXICO PLC (IXI)?
Our calculated price target is the estimate of £0.1078 (as of Nov 10, 2026). Cautious scenario £0.0809, optimistic scenario £0.1348. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the IXICO PLC stock forecast for 2026?
Our estimate puts fair value at £0.1078, about 16% lower versus a price of £0.1275 (overvalued). Cautious scenario £0.0809, optimistic scenario £0.1348. The calculation is refreshed regularly with new filings.
What is the revenue of IXICO PLC (IXI)?
IXICO PLC reported trailing-twelve-month revenue of about £7.3M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of IXICO PLC (IXI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IXICO PLC it is £0.1078 per share (as of Nov 10, 2026), against a price of £0.1275.
Is IXICO PLC stock overvalued or undervalued in 2026?
As of Nov 10, 2026, IXI trades above its calculated fair value: price £0.1275, fair value £0.1078, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IXI?
No. The price is what the market pays today (£0.1275); the fair value is what the company's own numbers justify (£0.1078). For IXICO PLC the two are £0.0197 per share apart. That gap is exactly why we show both numbers side by side.
How much is IXICO PLC worth?
The market values IXICO PLC at about £27.9M (market capitalisation, as of Nov 10, 2026). Per share that is £0.1275; our models calculate a fair value of £0.1078 per share.
What do the bullish and bearish scenarios say about IXI?
Our models span a range for IXICO PLC: cautious scenario £0.0809, base £0.1078, optimistic £0.1348 per share (as of Nov 10, 2026, price £0.1275). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of IXICO PLC (IXI)?
Balance-sheet figures for IXICO PLC (as of Nov 10, 2026): return on equity −15.8%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is IXI from its 52-week high?
IXICO PLC trades at £0.1275, about 18% below its 52-week high of £0.1550 and 92% above the low of £0.0663 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of £0.1078 is for.
Which stocks are comparable to IXICO PLC?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IXICO PLC stock attractive at the current price?
The data as of Nov 10, 2026: price £0.1275, calculated fair value £0.1078 (−16%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. IXICO PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IXICO PLC (IXI)?
The closing price on Nov 13, 2026 was £0.1275. Our estimate is £0.1078, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IXICO PLC right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of IXICO PLC

How large is the market capitalisation of IXICO PLC (IXI)?
The market capitalisation of IXICO PLC is £27.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IXICO PLC (IXI)?
The price-to-sales ratio of IXICO PLC is 3.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IXICO PLC (IXI)?
Earnings per share at IXICO PLC are £−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of IXICO PLC (IXI)?
The net margin of IXICO PLC is −25.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IXICO PLC (IXI)?
The return on equity (ROE) of IXICO PLC is −15.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IXICO PLC (IXI)?
On an EBIT basis the return on assets of IXICO PLC is −6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IXICO PLC (IXI)?
The operating margin of IXICO PLC is −31.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IXICO PLC (IXI)?
Revenue at IXICO PLC is growing +23.1% versus a year earlier (3y avg −8.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at IXICO PLC (IXI)?
Earnings per share at IXICO PLC are growing +20.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does IXICO PLC (IXI) generate?
The free cash flow of IXICO PLC is −£934K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does IXICO PLC (IXI) hold?
IXICO PLC holds more cash than debt, £3.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch IXICO PLC in the live analysis

One click puts IXICO PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.